Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Lalezari

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 9, 2015
Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIIIA Shah, H Delesen, S Garger, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 20, 2008
Infusion rates of recombinant FVIII-FS with PEGylated liposomes in haemophilia AU Martinowitz, S Lalezari, J Luboshitz, et al.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|June 6, 2015
Giant intracardiac blood cyst: assessing the relationship between its formation and previous cardiac surgeryJ Halim, F R N van Schaagen, R K Riezebos, et al.
Journal of Thrombosis and Haemostasis : JTH|November 7, 2006
Trp207Gly in platelet glycoprotein Ibalpha is a novel mutation that disrupts the connection between the leucine-rich repeat domain and the disulfide loop structure and causes Bernard-Soulier syndromeN Rosenberg, S Lalezari, M Landau, et al.
Circulation|December 14, 1999
Methylenetetrahydrofolate reductase genotypes and early-onset coronary artery diseaseA Mager, S Lalezari, T Shohat, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 21, 2013
Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FSS Lalezari, U Martinowitz, J Windyga, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 3, 2016
Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programmeJ Oldenburg, J Windyga, K Hampton, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 22, 2014
Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG studyS Lalezari, A Coppola, J Lin, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 25, 2016
Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trialK Saxena, S Lalezari, J Oldenburg, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 3, 2018
BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studiesA Shah, T Coyle, S Lalezari, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 9, 2015
Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIIIA Shah, H Delesen, S Garger, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 20, 2008
Infusion rates of recombinant FVIII-FS with PEGylated liposomes in haemophilia AU Martinowitz, S Lalezari, J Luboshitz, et al.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|June 6, 2015
Giant intracardiac blood cyst: assessing the relationship between its formation and previous cardiac surgeryJ Halim, F R N van Schaagen, R K Riezebos, et al.
Journal of Thrombosis and Haemostasis : JTH|November 7, 2006
Trp207Gly in platelet glycoprotein Ibalpha is a novel mutation that disrupts the connection between the leucine-rich repeat domain and the disulfide loop structure and causes Bernard-Soulier syndromeN Rosenberg, S Lalezari, M Landau, et al.
Circulation|December 14, 1999
Methylenetetrahydrofolate reductase genotypes and early-onset coronary artery diseaseA Mager, S Lalezari, T Shohat, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 21, 2013
Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FSS Lalezari, U Martinowitz, J Windyga, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 3, 2016
Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programmeJ Oldenburg, J Windyga, K Hampton, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 22, 2014
Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG studyS Lalezari, A Coppola, J Lin, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 25, 2016
Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trialK Saxena, S Lalezari, J Oldenburg, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 3, 2018
BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studiesA Shah, T Coyle, S Lalezari, et al.
Pageof 2